Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies
scSIGLEC1 levels are a promising biomarker for monitoring overall IIM disease activity, as well as activity involving the cutaneous, musculoskeletal, and gastrointestinal systems.
Authors
- V. Leclair
- Mark A. Tarnopolsky (ORCID: https://orcid.org/0000-0003-0312-3746)
- M. Fritzler
- Cristina Moran Toro
- May Y. Choi (ORCID: https://orcid.org/0000-0003-3760-2737)
- A Clarke (ORCID: https://orcid.org/0000-0003-2346-6818)
- Maude Bouchard-Marmen (ORCID: https://orcid.org/0000-0002-7246-9428)
- Sasha Bernatsky (ORCID: https://orcid.org/0000-0002-9515-2802)
- Eugene Krustev (ORCID: https://orcid.org/0000-0002-1812-2124)
- Yvan St. Pierre
- Nathan Barreth
- Josiane Bourré-Tessier
- Fergus Tol
- Océane Landon-Cardinal
- Canadian Inflammatory Myopathy Study
- Kun Huang
- Paul J A Sciore
- Marie Hudson
Institutions
- University of Calgary (CA)
- McMaster Children's Hospital (CA)
- Calgary Laboratory Services (CA)
- McGill University (CA)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2026-03-20
- DOI
- https://doi.org/10.1093/rheumatology/keag139
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00